HRP950250A2 - Novel dihydrodibenzoquinolinediones - Google Patents
Novel dihydrodibenzoquinolinediones Download PDFInfo
- Publication number
- HRP950250A2 HRP950250A2 HR08/233,998A HRP950250A HRP950250A2 HR P950250 A2 HRP950250 A2 HR P950250A2 HR P950250 A HRP950250 A HR P950250A HR P950250 A2 HRP950250 A2 HR P950250A2
- Authority
- HR
- Croatia
- Prior art keywords
- dihydro
- formula
- bis
- compound
- dibenz
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 30
- 206010028980 Neoplasm Diseases 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- 150000008064 anhydrides Chemical class 0.000 claims description 4
- RUANQJMORZSBEK-UHFFFAOYSA-N anthracene-1,9-dicarboxylic acid Chemical compound C1=CC=C2C(C(O)=O)=C3C(C(=O)O)=CC=CC3=CC2=C1 RUANQJMORZSBEK-UHFFFAOYSA-N 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- CKWYOIKYTYWDDP-UHFFFAOYSA-N C1(=CC=CC2=CC3=CC=CC=C3C(=C12)C(=O)O)C(=O)N Chemical compound C1(=CC=CC2=CC3=CC=CC=C3C(=C12)C(=O)O)C(=O)N CKWYOIKYTYWDDP-UHFFFAOYSA-N 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 150000004985 diamines Chemical class 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 125000001302 tertiary amino group Chemical group 0.000 claims description 2
- 125000004953 trihalomethyl group Chemical group 0.000 claims description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 150000004820 halides Chemical class 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229940098779 methanesulfonic acid Drugs 0.000 claims 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 90
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
- 238000002844 melting Methods 0.000 description 26
- 230000008018 melting Effects 0.000 description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 235000019441 ethanol Nutrition 0.000 description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- PGCKQBLIVWMPFF-UHFFFAOYSA-N n,n'-bis[2-(1,2-dihydro-1,3-dioxo-3h-dibenz[de,h]isoquinolin-2-yl)ethyl]-1,3-propanediamine Chemical compound C1=CC(C(=O)N(CCNCCCNCCN2C(C=3C4=CC=CC=C4C=C4C=CC=C(C=34)C2=O)=O)C2=O)=C3C2=C(C=CC=C2)C2=CC3=C1 PGCKQBLIVWMPFF-UHFFFAOYSA-N 0.000 description 12
- 239000007787 solid Substances 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- WHPWLUGDBCVLLK-UHFFFAOYSA-N 1,2-dihydro-3h-dibenz[de,h]isoquinoline-1,3-dione Chemical compound C1=CC(C(=O)NC2=O)=C3C2=C(C=CC=C2)C2=CC3=C1 WHPWLUGDBCVLLK-UHFFFAOYSA-N 0.000 description 3
- QBPVGVFLUWAMEQ-UHFFFAOYSA-N 2-(2-hydroxyethyl)-1,2-dihydro-3h-dibenz[de,h]isoquinoline-1,3-dione Chemical compound C1=CC=C2C(C(N(CCO)C3=O)=O)=C4C3=CC=CC4=CC2=C1 QBPVGVFLUWAMEQ-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- KSQMWIGJIDTOFT-UHFFFAOYSA-N anthracene-1,9-dicarboxylic anhydride Chemical compound C1=CC(C(=O)OC2=O)=C3C2=C(C=CC=C2)C2=CC3=C1 KSQMWIGJIDTOFT-UHFFFAOYSA-N 0.000 description 3
- -1 dicarboxylic acid halide Chemical class 0.000 description 3
- WHQSYGRFZMUQGQ-UHFFFAOYSA-N n,n-dimethylformamide;hydrate Chemical compound O.CN(C)C=O WHQSYGRFZMUQGQ-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- UWMHHZFHBCYGCV-UHFFFAOYSA-N 2,3,2-tetramine Chemical compound NCCNCCCNCCN UWMHHZFHBCYGCV-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- WAAQFJHSLKGGJO-UHFFFAOYSA-N 2-[2-(p-toluenesulfonyloxy)ethyl]-1,2-dihydro-3h-dibenz-[de,h]isoquinoline-1,3-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCN(C1=O)C(=O)C2=C3C1=CC=CC3=CC1=CC=CC=C12 WAAQFJHSLKGGJO-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- RSPOEUCVQSNRRK-UHFFFAOYSA-N ac1l7a3j Chemical compound C1=CC(C(=O)N(CCCNCCNCCCN2C(C=3C4=CC=CC=C4C=C4C=CC=C(C=34)C2=O)=O)C2=O)=C3C2=C(C=CC=C2)C2=CC3=C1 RSPOEUCVQSNRRK-UHFFFAOYSA-N 0.000 description 1
- SMJAADSKNHUJAN-UHFFFAOYSA-N ac1l7i2g Chemical compound C1=CC(C(=O)N(CCNCCN2C(C=3C4=CC=CC=C4C=C4C=CC=C(C=34)C2=O)=O)C2=O)=C3C2=C(C=CC=C2)C2=CC3=C1 SMJAADSKNHUJAN-UHFFFAOYSA-N 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- VFZBASYBHQKISE-UHFFFAOYSA-N chembl140742 Chemical compound C1=CC=C2C(C(N(CCN(CCN(C)CCN3C(C=4C5=CC=CC=C5C=C5C=CC=C(C=45)C3=O)=O)C)C3=O)=O)=C4C3=CC=CC4=CC2=C1 VFZBASYBHQKISE-UHFFFAOYSA-N 0.000 description 1
- SJLDCYXKABNRSN-UHFFFAOYSA-N chembl141593 Chemical compound C1=CC(C(=O)N(CCCNCCCNCCCN2C(C=3C4=CC=CC=C4C=C4C=CC=C(C=34)C2=O)=O)C2=O)=C3C2=C(C=CC=C2)C2=CC3=C1 SJLDCYXKABNRSN-UHFFFAOYSA-N 0.000 description 1
- MWWJJXMLIVMYCR-UHFFFAOYSA-N chembl141972 Chemical compound C1=CC(C(=O)N(CCNCCCCCNCCN2C(C=3C4=CC=CC=C4C=C4C=CC=C(C=34)C2=O)=O)C2=O)=C3C2=C(C=CC=C2)C2=CC3=C1 MWWJJXMLIVMYCR-UHFFFAOYSA-N 0.000 description 1
- GQOTWFRUVRGNFF-UHFFFAOYSA-N chembl142086 Chemical compound C1=CC(C(=O)N(CCNCCNCCN2C(C=3C4=CC=CC=C4C=C4C=CC=C(C=34)C2=O)=O)C2=O)=C3C2=C(C=CC=C2)C2=CC3=C1 GQOTWFRUVRGNFF-UHFFFAOYSA-N 0.000 description 1
- RDHISUVUWRZIJR-UHFFFAOYSA-N chembl265113 Chemical compound C1=CC(C(=O)N(CCCNCCCCNCCCN2C(C=3C4=CC=CC=C4C=C4C=CC=C(C=34)C2=O)=O)C2=O)=C3C2=C(C=CC=C2)C2=CC3=C1 RDHISUVUWRZIJR-UHFFFAOYSA-N 0.000 description 1
- RNJCIKCVFDNGIU-UHFFFAOYSA-N chembl335553 Chemical compound C1=CC=C2C(C(N(CCCN(CCCN3C(C=4C5=CC=CC=C5C=C5C=CC=C(C=45)C3=O)=O)C)C3=O)=O)=C4C3=CC=CC4=CC2=C1 RNJCIKCVFDNGIU-UHFFFAOYSA-N 0.000 description 1
- JRZHEOUJKULAST-UHFFFAOYSA-N chembl336040 Chemical compound C1=CC(C(=O)N(CCCNCCCN2C(C=3C4=CC=CC=C4C=C4C=CC=C(C=34)C2=O)=O)C2=O)=C3C2=C(C=CC=C2)C2=CC3=C1 JRZHEOUJKULAST-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- UCXVRPZYVHFUHP-UHFFFAOYSA-N dimethyl anthracene-1,9-dicarboxylate Chemical compound C1=CC=C2C(C(=O)OC)=C3C(C(=O)OC)=CC=CC3=CC2=C1 UCXVRPZYVHFUHP-UHFFFAOYSA-N 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 210000004692 intercellular junction Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- VHCPBLNDTKVHTI-UHFFFAOYSA-N n',n'-bis(2-aminoethyl)propane-1,3-diamine Chemical compound NCCCN(CCN)CCN VHCPBLNDTKVHTI-UHFFFAOYSA-N 0.000 description 1
- SCCWFEKONJHQAC-UHFFFAOYSA-N n,n'-bis[2-(1,2-dihydro-1,3-dioxo-3h-dibenz[de,h]isoquinolin-2-yl)ethyl]hexahydropyrimidine Chemical compound C1=CC(C(=O)N(CCN2CN(CCN3C(C=4C5=CC=CC=C5C=C5C=CC=C(C=45)C3=O)=O)CCC2)C2=O)=C3C2=C(C=CC=C2)C2=CC3=C1 SCCWFEKONJHQAC-UHFFFAOYSA-N 0.000 description 1
- HJFIJDDDBZCGTN-UHFFFAOYSA-N n-[2-(1,2-dihydro-1,3-dioxo-3h-dibenz[de,h]isoquinolin-2-yl)ethyl]-n'-(2-aminoethyl)-1,3-propanediamine Chemical compound C1=CC=C2C(C(N(CCNCCCNCCN)C3=O)=O)=C4C3=CC=CC4=CC2=C1 HJFIJDDDBZCGTN-UHFFFAOYSA-N 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23399894A | 1994-04-28 | 1994-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP950250A2 true HRP950250A2 (en) | 1997-10-31 |
Family
ID=22879465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR08/233,998A HRP950250A2 (en) | 1994-04-28 | 1995-04-25 | Novel dihydrodibenzoquinolinediones |
Country Status (11)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197785B1 (en) | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
| US6291425B1 (en) | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| US6121278A (en) * | 1997-09-03 | 2000-09-19 | Guilford Pharmaceuticals, Inc. | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity |
| US6380193B1 (en) | 1998-05-15 | 2002-04-30 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds, methods and compositions for inhibiting PARP activity |
| PT103503B (pt) | 2006-06-19 | 2009-05-18 | Univ Do Porto | Novos derivados do bisnaftalimidopropil, processo para a sua preparação, composições farmacêuticas que os contêm e sua utilização em doenças cancerígenas e parasitárias, nomeadamente leishmanioses, tripanossomíases e malária. |
| CN101638389B (zh) * | 2008-03-03 | 2012-09-05 | 河南大学 | 一种含萘酰亚胺结构的多胺衍生物及其制备方法和应用 |
| CN117074567B (zh) * | 2023-08-25 | 2025-06-27 | 四川汇宇制药股份有限公司 | 高效液相色谱法检测氨磷汀中间体纯度及其有关物质的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0125439B1 (en) * | 1983-04-01 | 1990-01-24 | Warner-Lambert Company | 3,6-disubstituted-1,8-naphthalimides and methods for their production and use |
| DE3707651A1 (de) * | 1987-03-10 | 1988-09-22 | Knoll Ag | Bis-naphthalimide, ihre herstellung und verwendung |
| CA2085598C (en) * | 1990-06-26 | 2002-09-17 | David S. Alberts | 1,2-dihydro-3h-dibenzisoquinoline-1,3-dione anticancer agents |
| JP3543196B2 (ja) * | 1992-09-11 | 2004-07-14 | リサーチ コーポレーション テクノロジーズ インコーポレーテッド | ６−エトキシ−２−［２’−（ジメチルアミノ）エチル］−１，２−ジヒドロ−３Ｈ−ジベンズ（ｄｅｈ）−イソキノリン−１，３−ジオン |
| DE4232739A1 (de) * | 1992-09-30 | 1994-03-31 | Knoll Ag | Neue asymmetrisch substituierte bis-Naphthalimide |
-
1995
- 1995-04-12 CN CN95193192A patent/CN1092185C/zh not_active Expired - Fee Related
- 1995-04-12 SG SG1996008471A patent/SG73418A1/en unknown
- 1995-04-12 AU AU23065/95A patent/AU2306595A/en not_active Abandoned
- 1995-04-12 WO PCT/EP1995/001347 patent/WO1995029895A1/en not_active Application Discontinuation
- 1995-04-12 CA CA002188833A patent/CA2188833A1/en not_active Abandoned
- 1995-04-12 EP EP95916636A patent/EP0757676A1/en not_active Withdrawn
- 1995-04-12 JP JP7527954A patent/JPH09512539A/ja not_active Ceased
- 1995-04-18 TW TW084103805A patent/TW307764B/zh active
- 1995-04-18 IL IL11341595A patent/IL113415A/xx not_active IP Right Cessation
- 1995-04-25 HR HR08/233,998A patent/HRP950250A2/hr not_active Application Discontinuation
- 1995-04-26 ZA ZA953379A patent/ZA953379B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW307764B (enrdf_load_stackoverflow) | 1997-06-11 |
| IL113415A (en) | 1999-11-30 |
| SG73418A1 (en) | 2000-06-20 |
| AU2306595A (en) | 1995-11-29 |
| CN1148851A (zh) | 1997-04-30 |
| IL113415A0 (en) | 1995-07-31 |
| CN1092185C (zh) | 2002-10-09 |
| JPH09512539A (ja) | 1997-12-16 |
| CA2188833A1 (en) | 1995-11-09 |
| EP0757676A1 (en) | 1997-02-12 |
| ZA953379B (en) | 1996-10-28 |
| WO1995029895A1 (en) | 1995-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH06263759A (ja) | 抗腫瘍組成物および治療方法 | |
| JPWO2002088112A1 (ja) | 複素環式化合物及びそれを有効成分とする抗腫瘍剤 | |
| US5789418A (en) | Bis-naphthalimides for the treatment of cancer | |
| GB1603228A (en) | Indole derivatives a process for preparing them and pharmaceutical compositions containing them | |
| US5703089A (en) | Dihydrodibenzisoquinolinediones | |
| CA2084643A1 (en) | Bis-naphthalimides anticancer agents | |
| HRP950250A2 (en) | Novel dihydrodibenzoquinolinediones | |
| US6147073A (en) | Substituted tetralymethylen-Oxindoles analogues as tyrosine kinase inhibitors | |
| US5905149A (en) | Substituted quinolymethylen-oxindole analogues as tyrosine kinase inhibitors | |
| EP1499595B1 (en) | Amonafide salts | |
| US20050222418A1 (en) | Novel tyloindicines and related processes, pharmaceutical compositions and methods | |
| CN110156817A (zh) | 双吴茱萸碱分子抗肿瘤衍生物及其制备与应用 | |
| Brana et al. | Synthesis, structure and cytostatic activity of a series of 2-substituted perimidines | |
| US5359070A (en) | Unsymmetrical bis-imides as anticancer agents | |
| JPH05504124A (ja) | １，４―ビス（アルキルアミノ）―２，３―ジアザ―アントラセン―９，１０―ジオン類 | |
| CA2349451A1 (en) | Substituted diazaanthracene compounds having pharmaceutical utility | |
| WO1994005641A1 (en) | 4-SUBSTITUTED 6,9,-BIS (SUBSTITUTED-AMINO) BENZO [g] ISOQUINOLINE-5,10,DIONES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20020425 Year of fee payment: 8 |
|
| ODBI | Application refused |